{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:33:14Z","timestamp":1790656394656,"version":"4.1.0"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.exphem.2022.03.008","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T12:14:46Z","timestamp":1647432886000},"page":"20-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without DNMT3A mutations"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4066-7953","authenticated-orcid":false,"given":"Daniil E.","family":"Shabashvili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2784-1470","authenticated-orcid":false,"given":"Prabhjot","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartika","family":"Venugopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6514-8466","authenticated-orcid":false,"given":"Olga A.","family":"Guryanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2022.03.008_bib0001","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.03.008_bib0002","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.critrevonc.2016.12.004","article-title":"Frontline treatment of acute myeloid leukemia in adults","volume":"110","author":"Tamamyan","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.exphem.2022.03.008_bib0003","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.03.008_bib0004","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1158\/1078-0432.CCR-14-0327","article-title":"DNMT3A mutational status affects the results of dose-escalated induction therapy in acute myelogenous leukemia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2022.03.008_bib0005","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.03.008_bib0006","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1016\/S2352-3026(18)30132-7","article-title":"Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial","volume":"5","author":"Kadia","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.exphem.2022.03.008_bib0007","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1158\/1078-0432.CCR-21-2863","article-title":"DNMT3A harboring leukemia-associated mutations directs sensitivity to DNA damage at replication forks","volume":"28","author":"Venugopal","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2022.03.008_bib0008","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030320","article-title":"DNMT3A in leukemia","volume":"7","author":"Brunetti","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.exphem.2022.03.008_bib0009","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.03.008_bib0010","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","article-title":"DNMT3A mutations in acute myeloid leukemia","volume":"363","author":"Ley","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.03.008_bib0011","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.03.008_bib0012","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/ng.788","article-title":"Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia","volume":"43","author":"Yan","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2022.03.008_bib0013","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1158\/0008-5472.CAN-20-3033","article-title":"Alterations to DNMT3A in hematologic Malignancies","volume":"81","author":"Venugopal","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2022.03.008_bib0014","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/nm.4210","article-title":"DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling","volume":"22","author":"Guryanova","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2022.03.008_bib0015","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ccr.2014.02.010","article-title":"The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers","volume":"25","author":"Russler-Germain","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2022.03.008_bib0016","doi-asserted-by":"crossref","first-page":"18207","DOI":"10.1074\/jbc.RA119.010827","article-title":"The R882H substitution in the human de novo DNA methyltransferase DNMT3A disrupts allosteric regulation by the tumor supressor p53","volume":"294","author":"Sandoval","year":"2019","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2022.03.008_bib0017","doi-asserted-by":"crossref","first-page":"11355","DOI":"10.1093\/nar\/gkz911","article-title":"Mutations of R882 change flanking sequence preferences of the DNA methyltransferase DNMT3A and cellular methylation patterns","volume":"47","author":"Emperle","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.exphem.2022.03.008_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106372","article-title":"DNMT3A alterations associated with myeloid malignancies dictate differential responses to hypomethylating agents","volume":"94","author":"Casellas Roman","year":"2020","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2022.03.008_bib0019","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.3390\/cancers13164189","article-title":"Cladribine combined with low-dose cytarabine as frontline treatment for unfit elderly acute myeloid leukemia patients: Results from a prospective multicenter study of Polish Adult Leukemia Group (PALG)","volume":"13","author":"Budziszewska","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.exphem.2022.03.008_bib0020","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/ajh.26206","article-title":"Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia","volume":"96","author":"Kadia","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2022.03.008_bib0021","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.03.008_bib0022","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1010222","article-title":"Cytarabine dose for acute myeloid leukemia","volume":"364","author":"Lowenberg","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.03.008_bib0023","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/leu.2015.38","article-title":"A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia","volume":"29","author":"Burnett","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.03.008_bib0024","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.2217\/pgs.09.118","article-title":"Genetic factors influencing cytarabine therapy","volume":"10","author":"Lamba","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.exphem.2022.03.008_bib0025","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","article-title":"Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.03.008_bib0026","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/ajh.24246","article-title":"Acute myeloid leukemia\u2014major progress over four decades and glimpses into the future","volume":"91","author":"Kantarjian","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2022.03.008_bib0027","doi-asserted-by":"crossref","first-page":"6522","DOI":"10.1038\/onc.2008.316","article-title":"Nucleoside analogs: molecular mechanisms signaling cell death","volume":"27","author":"Ewald","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2022.03.008_bib0028","doi-asserted-by":"crossref","first-page":"9063","DOI":"10.1038\/sj.onc.1207229","article-title":"Mechanisms of apoptosis induction by nucleoside analogs","volume":"22","author":"Sampath","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2022.03.008_bib0029","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41580-020-0257-5","article-title":"The plasticity of DNA replication forks in response to clinically relevant genotoxic stress","volume":"21","author":"Berti","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.exphem.2022.03.008_bib0030","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2897","article-title":"Causes and consequences of replication stress","volume":"16","author":"Zeman","year":"2014","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.exphem.2022.03.008_bib0031","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3109\/10428190903582804","article-title":"Acute myeloid leukemia outcome: role of nucleotide excision repair polymorphisms in intermediate risk patients","volume":"51","author":"Strom","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2022.03.008_bib0032","doi-asserted-by":"crossref","first-page":"eaaz4126","DOI":"10.1126\/sciadv.aaz4126","article-title":"Mre11 exonuclease activity removes the chain-terminating nucleoside analogue gemcitabine from the nascent strand during DNA replication","volume":"6","author":"Boeckemeier","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.exphem.2022.03.008_bib0033","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1182\/blood-2009-05-220376","article-title":"Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC","volume":"116","author":"Liu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.03.008_bib0034","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood.2019003782","article-title":"SLFN11 promotes stalled fork degradation that underlies the phenotype in Fanconi anemia cells","volume":"137","author":"Okamoto","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.03.008_bib0035","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.exphem.2022.03.008_bib0036","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.exphem.2022.03.008_bib0037","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.exphem.2022.03.008_bib0038","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1182\/bloodadvances.2021004638","article-title":"PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome","volume":"5","author":"Kontandreopoulou","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2022.03.008_bib0039","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.cell.2013.10.043","article-title":"ATR prohibits replication catastrophe by preventing global exhaustion of RPA","volume":"155","author":"Toledo","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2022.03.008_bib0040","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.142149","article-title":"Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS\/AML","volume":"6","author":"Tothova","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.exphem.2022.03.008_bib0041","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1182\/blood-2021-149688","article-title":"Spliceosome mutant myeloid malignancies are preferentially sensitive to PARP inhibition","volume":"138","author":"Nguyen","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.03.008_bib0042","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1158\/1078-0432.CCR-15-2351","article-title":"Poly(ADP-ribose) polymerase inhibitor hypersensitivity in aggressive myeloproliferative neoplasms","volume":"22","author":"Pratz","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2022.03.008_bib0043","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/nm.3993","article-title":"Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors","volume":"21","author":"Esposito","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2022.03.008_bib0044","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1158\/1078-0432.CCR-17-2796","article-title":"IDH1\/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1\/2-mutant inhibitors","volume":"24","author":"Molenaar","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2022.03.008_bib0045","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1182\/blood-2017-05-784942","article-title":"Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms","volume":"130","author":"Nieborowska-Skorska","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.03.008_bib0046","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1182\/bloodadvances.2017006247","article-title":"MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs","volume":"1","author":"Maifrede","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2022.03.008_bib0047","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ccell.2016.09.002","article-title":"Enhancing the cytotoxic effects of PARP inhibitors with DNA demethylating agents\u2014a potential therapy for cancer","volume":"30","author":"Muvarak","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2022.03.008_bib0048","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1182\/blood-2021-153884","article-title":"Vitamin C enhances PARPi efficacy for the treatment of AML","volume":"138","author":"Brabson","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.03.008_bib0049","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1172\/JCI97992","article-title":"A PET imaging agent for evaluating PARP-1 expression in ovarian cancer","volume":"128","author":"Makvandi","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2022.03.008_bib0050","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.1158\/0008-5472.CAN-20-3761","article-title":"TET2 and DNMT3A mutations exert divergent effects on DNA repair and sensitivity of leukemia cells to PARP inhibitors","volume":"81","author":"Maifrede","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2022.03.008_bib0051","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2022.03.008_bib0052","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1182\/blood-2005-03-1240","article-title":"The kinetics of clonal dominance in myeloproliferative disorders","volume":"106","author":"SN","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.03.008_bib0053","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/bloodadvances.2018023705","article-title":"Visualizing hematopoiesis as a stochastic process","volume":"2","author":"Xu","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2022.03.008_bib0054","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41586-018-0497-0","article-title":"Population dynamics of normal human blood inferred from somatic mutations","volume":"561","author":"Lee-Six","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2022.03.008_bib0055","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1126\/science.aay9333","article-title":"The evolutionary dynamics and fitness landscape of clonal hematopoiesis","volume":"367","author":"Watson","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.exphem.2022.03.008_bib0056","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41586-018-0811-x","article-title":"Age-related remodelling of oesophageal epithelia by mutated cancer drivers","volume":"565","author":"Yokoyama","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2022.03.008_bib0057","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41588-020-0624-3","article-title":"Spatial competition shapes the dynamic mutational landscape of normal esophageal epithelium","volume":"52","author":"Colom","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2022.03.008_bib0058","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1126\/science.aaa6806","article-title":"Tumor evolution: high burden and pervasive positive selection of somatic mutations in normal human skin","volume":"348","author":"Martincorena","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.exphem.2022.03.008_bib0059","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41586-020-2214-z","article-title":"The mutational landscape of normal human endometrial epithelium","volume":"580","author":"Moore","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2022.03.008_bib0060","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41586-019-1672-7","article-title":"The landscape of somatic mutation in normal colorectal epithelial cells","volume":"574","author":"Lee-Six","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2022.03.008_bib0061","doi-asserted-by":"crossref","first-page":"eaan4673","DOI":"10.1126\/science.aan4673","article-title":"Clonal hematopoiesis in human aging and disease","volume":"366","author":"Jaiswal","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.exphem.2022.03.008_bib0062","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","article-title":"Prediction of acute myeloid leukaemia risk in healthy individuals","volume":"559","author":"Abelson","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2022.03.008_bib0063","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.03.008_bib0064","article-title":"Inherited causes of clonal hematopoiesis of indeterminate potential in TOPMed whole genomes","author":"Bick","year":"2019","journal-title":"bioRxiv"},{"key":"10.1016\/j.exphem.2022.03.008_bib0065","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41591-018-0081-z","article-title":"Somatic mutations precede acute myeloid leukemia years before diagnosis","volume":"24","author":"Desai","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.exphem.2022.03.008_bib0066","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.03.008_bib0067","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","article-title":"Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case\u2013control study","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2022.03.008_bib0068","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2022.03.008_bib0069","doi-asserted-by":"crossref","first-page":"5918","DOI":"10.1158\/1078-0432.CCR-18-1201","article-title":"Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired next-generation sequencing assays","volume":"24","author":"Coombs","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2022.03.008_bib0070","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2022.03.008_bib0071","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41375-021-01382-3","article-title":"Cross NCP. Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease","volume":"36","author":"Dawoud","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.03.008_bib0072","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1182\/blood.2021013531","article-title":"Association of clonal hematopoiesis with chronic obstructive pulmonary disease","volume":"139","author":"Miller","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.03.008_bib0073","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1182\/blood-2017-04-777029","article-title":"DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions","volume":"130","author":"Buscarlet","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.03.008_bib0074","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1182\/bloodadvances.2020004062","article-title":"Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged >\/=80 years","volume":"5","author":"van Zeventer","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2022.03.008_bib0075","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2022.03.008_bib0076","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1038\/s41375-020-0896-8","article-title":"Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking","volume":"34","author":"Dawoud","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.03.008_bib0077","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.stem.2021.03.002","article-title":"Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNgamma signaling","volume":"28","author":"Hormaechea-Agulla","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2022.03.008_bib0078","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","article-title":"PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy","volume":"23","author":"Hsu","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2022.03.008_bib0079","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1200\/JCO.2020.38.15_suppl.1513","article-title":"The impact of poly ADP ribose polymerase (PARP) inhibitors on clonal hematopoiesis","volume":"38","author":"Bolton","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2022.03.008_bib0080","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1470-2045(16)30627-1","article-title":"Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case\u2013control study","volume":"18","author":"Gillis","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2022.03.008_bib0081","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: A safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.exphem.2022.03.008_bib0082","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2022.03.008_bib0083","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2641","article-title":"p53 mutations in cancer","volume":"15","author":"Muller","year":"2013","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.exphem.2022.03.008_bib0084","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1002\/cncr.30203","article-title":"TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes","volume":"122","author":"Kadia","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2022.03.008_bib0085","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s12185-016-1942-1","article-title":"TP53 mutations in older adults with acute myeloid leukemia","volume":"103","author":"Yanada","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.exphem.2022.03.008_bib0086","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/humu.10190","article-title":"TP53 in hematological cancer: low incidence of mutations with significant clinical relevance","volume":"21","author":"Peller","year":"2003","journal-title":"Hum Mutat"},{"key":"10.1016\/j.exphem.2022.03.008_bib0087","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1182\/blood.V82.9.2617.2617","article-title":"The human MDM-2 oncogene is overexpressed in leukemias","volume":"82","author":"Bueso-Ramos","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.03.008_bib0088","doi-asserted-by":"crossref","first-page":"933","DOI":"10.18632\/oncotarget.1559","article-title":"High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia","volume":"5","author":"Tan","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2022.03.008_bib0089","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1182\/blood-2005-02-0553","article-title":"MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy","volume":"106","author":"Kojima","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.03.008_bib0090","doi-asserted-by":"crossref","first-page":"eaao3003","DOI":"10.1126\/scitranslmed.aao3003","article-title":"Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia","volume":"10","author":"Carvajal","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.exphem.2022.03.008_bib0091","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1021\/acs.jmedchem.8b00909","article-title":"Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting chimera murine double minute 2 degrader capable of achieving complete and durable tumor regression","volume":"62","author":"Li","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.exphem.2022.03.008_bib0092","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1021\/acs.jmedchem.8b01945","article-title":"Targeted degradation of MDM2 as a new approach to improve the efficacy of MDM2-p53 inhibitors","volume":"62","author":"Wurz","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.exphem.2022.03.008_bib0093","doi-asserted-by":"crossref","first-page":"10621","DOI":"10.1021\/acs.jmedchem.1c00940","article-title":"Recent progress and clinical development of inhibitors that block MDM4\/p53 protein\u2013protein interactions","volume":"64","author":"Zhang","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.exphem.2022.03.008_bib0094","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.03.008_bib0095","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.26039","article-title":"Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study","volume":"96","author":"Pollyea","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2022.03.008_bib0096","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13045-021-01169-0","article-title":"Targeting mutant p53 for cancer therapy: direct and indirect strategies","volume":"14","author":"Hu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.exphem.2022.03.008_bib0097","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","article-title":"MDM2 inhibition: an important step forward in cancer therapy","volume":"34","author":"Konopleva","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.03.008_bib0098","doi-asserted-by":"crossref","first-page":"10782","DOI":"10.3390\/ijms221910782","article-title":"TP53 in acute myeloid leukemia: molecular aspects and patterns of mutation","volume":"22","author":"George","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.exphem.2022.03.008_bib0099","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2022.03.008_bib0100","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/ijc.25365","article-title":"DNMT3a plays a role in switches between doxorubicin-induced senescence and apoptosis of colorectal cancer cells","volume":"128","author":"Zhang","year":"2011","journal-title":"Int J Cancer"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X22001254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X22001254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:37:46Z","timestamp":1759567066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X22001254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":100,"alternative-id":["S0301472X22001254"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2022.03.008","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without DNMT3A mutations","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2022.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}